PTCH1 and pachyonychia congenita: More specifically, the data from immunohistochemical analyses of SHH, PTCH and GLI-1 in 155 cases of PC have indicated that the enhanced expression of these proteins was significantly associated with poor prognostic parameters, including a larger tumor size, high serum prostate-specific antigen (PSA) levels, high Gleason score, perineural invasion and anatomic stage/prognostic groups (ASPG) [18].